Pioneer Use of Lentiviral Vector Platform
Next-Generation Vaccination against Cancers & Infectious Diseases
TheraVectys is a biotechnology partner from the prestigious Institut Pasteur.
The company has developed a breakthrough vaccine platform based on Lentiviral Vectors.
Establish a new generation of immunotherapies capable of preventing, treating, and curing severe conditions with unmet medical needs, including cancers and chronic viral infections.
Directly targets and controls dendritic cells to trigger a potent and long-lasting cellular immune response (T-cell immunity) alongside standard antibody production.
Over €100 Million invested in our proprietary vaccine platform incorporating lentiviral vectors and custom-designed antigens, backed by exclusive global licensing agreements covering foundational patents.
Prophylactic and therapeutic vaccination
There is a globally unmet and critical medical need to prevent and treat infectious disease and cancer.
We support patients and healthcare providers by developing prophylactic and therapeutic
immunotherapies across a diverse pipeline, covering:
comprising 19 product candidates at various stages of development
as of the latest practicable date.